Research ArticleOriginal Article
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair
Yangyang Kong, Chang Xu, Xiaohui Sun, Hao Sun, Xiaotong Zhao, Ningning He, Kaihua Ji, Qin Wang, Liqing Du, Jinhan Wang, Manman Zhang, Yang Liu, Yan Wang and Qiang Liu
Cancer Biology & Medicine July 2022, 20210178; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0178
Yangyang Kong
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Chang Xu
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Xiaohui Sun
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Hao Sun
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Xiaotong Zhao
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Ningning He
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Kaihua Ji
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Qin Wang
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Liqing Du
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Jinhan Wang
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Manman Zhang
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Yang Liu
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Yan Wang
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
Qiang Liu
1Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
References
- 1.↵Addario BJ. Lung cancer is a global epidemic and requires a global effort. Ann Transl Med. 2015; 3: 26–28.
- 2.↵
- 3.↵Chu DT, Zhang XR, Li JL, Qu FL, Sun Y. The treatment of advanced non-small cell lung cancer (NSCLC)-overseas updated and local experiences. Gan To Kagaku Ryoho. 2002; 29: 117–24.
- 4.↵Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351–60.
- 5.↵Mikell JL, Gillespie TW, Hall WA, Nickleach DC, Liu Y, Lipscomb J, et al. Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. J Thorac Oncol. 2015; 10: 462–71.
- 6.↵
- 7.↵
- 8.↵Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004; 26: 882–93.
- 9.Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet. 2008; 9: 619–31.
- 10.↵Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006; 7: 517–28.
- 11.↵Gadducci A, Guerrieri ME. PARP inhibitors in epithelial ovarian cancer: state of art and perspectives of clinical research. Anticancer Res. 2016; 36: 2055–64.
- 12.Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014; 25: 32–40.
- 13.↵
- 14.↵Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009; 1: 315–22.
- 15.Sourisseau T, Maniotis D, McCarthy A, Tang C, Lord CJ, Ashworth A, et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med. 2010; 2: 130–42.
- 16.↵Williamson CT, Muzik H, Turhan AG, Zamò A, O’Connor MJ, Bebb DG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-Ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010; 9: 347–57.
- 17.↵Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013; 19: 5003–15.
- 18.↵de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, et al. Study protocols of 3 parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer. 2019; 19: 901–13.
- 19.↵
- 20.↵Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K, et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev. 2010; 36: 566–75.
- 21.↵Chu WK, Hickson ID. RecQ helicases: multifunctional genome caretaker. Nat Rev Cancer. 2009; 9: 644–54.
- 22.↵
- 23.Van Brabant AJ, Ye T, Sanz M, German III JL, Ellis NA, Holloman WK. Binding and melting of D-loops by the Bloom syndrome helicase. Biochemistry. 2000; 39: 14617–25.
- 24.↵Wu L, Hickson ID. The Bloom’s syndrome helicase suppresses crossing over during homologous recombination. Nature. 2003; 426: 870–4.
- 25.↵
- 26.↵
- 27.↵
- 28.
- 29.↵Yin QK, Wang CX, Wang YQ, Guo QL, Zhang ZL, Ou TM, et al. Discovery of isaindigotone derivatives as novel Bloom’s syndrome protein (BLM) helicase inhibitors that disrupt the BLM/DNA interactions and regulate the homologous recombination repair. J Med Chem. 2019; 62: 3147–62.
- 30.↵Wang CX, Zhang ZL, Yin QK, Tu JL, Wang JE, Xu YH, et al. Design, synthesis, and evaluation of new quinazolinone derivatives that inhibit Bloom syndrome protein (BLM) helicase, trigger DNA damage at the telomere region, and synergize with PARP inhibitors. J Med Chem. 2020; 63: 9752–72.
- 31.↵Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001; 27: 247–54.
- 32.↵Modesti M, Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol. 2001; 11: R229–R32.
- 33.↵Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie. 2003; 85: 1161–73.
- 34.↵van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet. 2001; 2: 196–06.
- 35.↵Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 1998; 23: 247–51.
- 36.↵Uematsu N, Weterings E, Yano K, Morotomi-Yano K, Jakob B, Taucher-Scholz G, et al. Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. J Cell Biol. 2007; 177: 219–29.
- 37.↵Liu T, Huang J. DNA end resection: facts and mechanisms. Genom Proteom Bioinf. 2016; 14: 126–30.
- 38.↵
- 39.↵Rulten SL, Grundy GJ. Non-homologous end joining: common interaction sites and exchange of multiple factors in the DNA repair process. Bioessays. 2017; 39–50.
- 40.↵Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2007; 434: 913–7.
- 41.↵Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009; 21: 245–55.
- 42.↵LaGory EL, Sitailo LA, Denning MF. The protein kinase Cdelta catalytic fragment is critical for maintenance of the G2/M DNA damage checkpoint. J Biol Chem. 2010; 285: 1879–87.
- 43.↵Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 1991; 10: 4279–90.
- 44.↵Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282: 1497–501.
- 45.↵Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015; 3: 1257–68.
- 46.↵
- 47.↵Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, et al. Combinatorial efficacy of olaparib with radiation and ATR Inhibitor requires PARP1 protein in homologous recombination-proficient pancreatic cancer. Mol Cancer Ther. 2021; 20: 263–73.
- 48.↵Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O’Connor MJ, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011; 10: 1949–58.
- 49.↵
- 50.↵Wang H, Li S, Zhang H, Wang Y, Hao S, Wu X. BLM prevents instability of structure-forming DNA sequences at common fragile sites. PLOS Genet. 2018; 14: e1007816–38.
- 51.Datta A, Dhar S, Awate S, Brosh RM. Synthetic lethal interactions of RECQ helicases. Trends Cancer. 2021; 7: 146–61.
- 52.↵Chen X, Ali YI, Fisher CE, Arribas-Bosacoma R, Rajasekaran MB, Williams G, et al. Uncovering an allosteric mode of action for a selective inhibitor of human Bloom syndrome protein. Elife. 2021; 10: e65339–70.
- 53.↵Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly (ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010; 70: 5389–98.
- 54.↵
- 55.↵
- 56.↵Otsuki M, Seki M, Inoue E, Yoshimura A, Kato G, Yamanouchi S, et al. Functional interactions between BLM and XRCC3 in the cell. J Cell Biol. 2007; 179: 53–63.
- 57.↵Patel DS, Misenko SM, Her J, Bunting SF. BLM helicase regulates DNA repair by counteracting RAD51 loading at DNA double-strand break sites. J Cell Biol. 2017; 216: 3521–34.
- 58.↵Gravel S, Chapman JR, Magill C, Jackson SP. DNA helicases Sgs1 and BLM promote DNA double-strand break resection. Genes Dev. 2008; 22: 2767–72.
- 59.↵Nimonkar AV, Ozsoy AZ, Genschel J, Modrich P, Kowalczykowski SC. Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair. Proc Natl Acad Sci U S A. 2008; 105: 16906–11.
- 60.↵Wang W, Duan B, Zeng L. Effect and mechanism of radiosensitization of poly (ADP-Ribose) polymerase inhibitor in Lewis cells and xenografts. Zhongguo Fei Ai Za Zhi. 2016; 19: 16–23.
- 61.↵Hirai T, Saito S, Fujimori H, Matsushita K, Nishio T, Okayasu R, et al. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells. Biochem Biophys Res Commun. 2016; 478: 234–40.
- 62.↵Bischof O, Kim SH, Irving J, Ellis NA, Campisi J. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol. 2001; 153: 367–80.
- 63.↵Dutertre S, Ababou M, Onclercq R, Delic J, Chatton B, Jaulin C, et al. Cell cycle regulation of the endogenous wild type Bloom’s syndrome DNA helicase. Oncogene. 2000; 19: 2731–8.
- 64.↵Chapman JR, Sossick AJ, Boulton SJ, Jackson SP. BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair. J Cell Sci. 2012; 125: 3529–34.
- 65.↵Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917–21.
- 66.Hilton JF, Hadfield MJ, Tran MT, Shapiro GI. Poly (ADP-ribose) polymerase inhibitors as cancer therapy. Front Biosci (Landmark Ed). 2013; 18: 1392–406.
- 67.↵Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood. 2011; 117: 6074–82.
In this issue
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair
Yangyang Kong, Chang Xu, Xiaohui Sun, Hao Sun, Xiaotong Zhao, Ningning He, Kaihua Ji, Qin Wang, Liqing Du, Jinhan Wang, Manman Zhang, Yang Liu, Yan Wang, Qiang Liu
Cancer Biology & Medicine Jul 2022, 20210178; DOI: 10.20892/j.issn.2095-3941.2021.0178
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair
Yangyang Kong, Chang Xu, Xiaohui Sun, Hao Sun, Xiaotong Zhao, Ningning He, Kaihua Ji, Qin Wang, Liqing Du, Jinhan Wang, Manman Zhang, Yang Liu, Yan Wang, Qiang Liu
Cancer Biology & Medicine Jul 2022, 20210178; DOI: 10.20892/j.issn.2095-3941.2021.0178
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.